UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Volltextzugriff (PDF)

Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder

European journal of clinical pharmacology, 2019-04, Vol.75 (4), p.519-528

2019

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

The ISoP Standards and Best Practices Committee

Clinical pharmacology and therapeutics, 2014-06, Vol.95 (6), p.581-582

2014

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients

Infectious diseases now (Online), 2023-02, Vol.53 (1), p.104625, Article 104625

2023

Volltextzugriff (PDF)

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2014-04, Vol.3 (4), p.1-9

2014

Volltextzugriff (PDF)

Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records

Antimicrobial agents and chemotherapy, 2023-05, Vol.67 (5), p.e0233918-e0233918

2023

Volltextzugriff (PDF)

Role of modelling and simulation in Phase I drug development

European journal of pharmaceutical sciences, 2001-05, Vol.13 (2), p.115-122

2001

Volltextzugriff (PDF)

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package

Anticancer research, 1994-11, Vol.14 (6A), p.2321

1994

Volltextzugriff (PDF)

Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder

Drug design, development and therapy, 2014, Vol.8 (default), p.2321-2332

2014

Volltextzugriff (PDF)

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

British journal of clinical pharmacology, 2005-10, Vol.60 (4), p.390-403

2005

Volltextzugriff (PDF)

Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Journal of pharmacokinetics and pharmacodynamics, 2001-06, Vol.28 (3), p.299-319

2001

Volltextzugriff (PDF)

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

British journal of clinical pharmacology, 2008-04, Vol.65 (4), p.548-557

2008

Volltextzugriff (PDF)

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

European journal of clinical pharmacology, 2009-07, Vol.65 (7), p.667-678

2009

Volltextzugriff (PDF)

Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software

European journal of clinical pharmacology, 1994-06, Vol.46 (5), p.389-391

1994

Volltextzugriff (PDF)

Bayesian design criteria : computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model

Journal of pharmacokinetics and biopharmaceutics, 1995-02, Vol.23 (1), p.101-125

1995

Volltextzugriff (PDF)

Handling covariates in population pharmacokinetics

International journal of bio-medical computing, 1994-06, Vol.36 (1), p.25-33

1994

Volltextzugriff (PDF)

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics

Journal of pharmacokinetics and biopharmaceutics, 1998-12, Vol.26 (6), p.689-716

1998

Volltextzugriff (PDF)

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis : An application to basiliximab in renal transplantation

Journal of pharmacokinetics and biopharmaceutics, 1999-04, Vol.27 (2), p.213-230

1999

Volltextzugriff (PDF)

New strategies in drug development and clinical evaluation : the population approach : commentary on an action for co-operative research

European journal of clinical pharmacology, 1993-09, Vol.45 (2), p.93-94

1993

Volltextzugriff (PDF)

Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: Application in pharmacokinetics

Mathematical biosciences, 1997-08, Vol.144 (1), p.45-70

1997

Volltextzugriff (PDF)

Non-linear mixed effects modeling : From methodology and software development to driving implementation in drug development science

Journal of pharmacokinetics and pharmacodynamics, 2005-04, Vol.32 (2), p.161-183

2005

Volltextzugriff (PDF)

Optimization of individual and population designs using Splus

Journal of pharmacokinetics and pharmacodynamics, 2003-12, Vol.30 (6), p.417-443

2003

Volltextzugriff (PDF)

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

Journal of pharmacokinetics and biopharmaceutics, 1998-04, Vol.26 (2), p.133-161

1998

Volltextzugriff (PDF)

Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies

European journal of clinical pharmacology, 1996, Vol.49 (4), p.251-254

1996

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaPhysical Sciences

ThemaPharmacokinetics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

The ISoP Standards and Best Practices Committee

Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records

Role of modelling and simulation in Phase I drug development

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package

Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder

Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV‐infected patients on HAART

Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software

Bayesian design criteria : computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model

Handling covariates in population pharmacokinetics

Robust optimal design for the estimation of hyperparameters in population pharmacokinetics

Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis : An application to basiliximab in renal transplantation

New strategies in drug development and clinical evaluation : the population approach : commentary on an action for co-operative research

Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: Application in pharmacokinetics

Non-linear mixed effects modeling : From methodology and software development to driving implementation in drug development science

Optimization of individual and population designs using Splus

Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method

Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies

Aktive Filter

Suchergebnisse filtern